From post

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

, , , , , , , , , , , и . Nat. Med., 5 (6): 677-685 (июня 1999)LR: 20071115; GR: CA-42509/CA/NCI NIH HHS/United States; GR: CA-81543/CA/NCI NIH HHS/United States; GR: K08 CA72976/CA/NCI NIH HHS/United States; JID: 9502015; 0 (Antigens, CD28); 0 (Antigens, CD44); 0 (Antigens, CD57); 0 (Antigens, Neoplasm); 0 (Antineoplastic Agents); 0 (HLA-A2 Antigen); 0 (MART1 antigen); 0 (Membrane Glycoproteins); 0 (Neoplasm Proteins); 0 (Peptide Fragments); 0 (Receptors, IgG); 0 (Recombinant Proteins); 0 (melanocyte lineage-specific antigen gp100); EC 1.14.18.1 (Monophenol Monooxygenase); EC 3.1.3.48 (Antigens, CD45); ppublish.

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed.

 

Другие публикации лиц с тем же именем

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, , , , , , , , , и 2 other автор(ы). Nat. Med., 5 (6): 677-685 (июня 1999)LR: 20071115; GR: CA-42509/CA/NCI NIH HHS/United States; GR: CA-81543/CA/NCI NIH HHS/United States; GR: K08 CA72976/CA/NCI NIH HHS/United States; JID: 9502015; 0 (Antigens, CD28); 0 (Antigens, CD44); 0 (Antigens, CD57); 0 (Antigens, Neoplasm); 0 (Antineoplastic Agents); 0 (HLA-A2 Antigen); 0 (MART1 antigen); 0 (Membrane Glycoproteins); 0 (Neoplasm Proteins); 0 (Peptide Fragments); 0 (Receptors, IgG); 0 (Recombinant Proteins); 0 (melanocyte lineage-specific antigen gp100); EC 1.14.18.1 (Monophenol Monooxygenase); EC 3.1.3.48 (Antigens, CD45); ppublish.